Transform-1: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, International Phase 3 Study of Navitoclax in Combination with Ruxolitinib Versus Ruxolitinib Plus Placebo in Patients with Untreated Myelofibrosis

Naveen Pemmaraju, Adam J Mead, Tim CP Somervaille, James K McCloskey, Francesca Palandri, Steffen Koschmieder, David Lavie, Brian Leber, Su-Peng Yeh, Maria Teresa Gómez-Casares, Emanuele Ammatuna, Ho-Jin Shin, Keita Kirito, Eric Jourdan, Timothy Devos, Hun S Chuah, Atanas Radinoff, Andrija Bogdanovic, Rastislav Moskal, Qi Jiang, Avijeet S Chopra, Elektra Papadopoulos, Jalaja Potluri, Francesco Passamonti

Open source

DOI: 10.1182/blood-2023-173509
Published: 2023-11-02
Container: Blood
Publisher: American Society of Hematology
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1182/blood-2023-173509,
  title = {Transform-1: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, International Phase 3 Study of Navitoclax in Combination with Ruxolitinib Versus Ruxolitinib Plus Placebo in Patients with Untreated Myelofibrosis},
  author = {Naveen Pemmaraju and Adam J Mead and Tim CP Somervaille and James K McCloskey and Francesca Palandri and Steffen Koschmieder and David Lavie and Brian Leber and Su-Peng Yeh and Maria Teresa Gómez-Casares and Emanuele Ammatuna and Ho-Jin Shin and Keita Kirito and Eric Jourdan and Timothy Devos and Hun S Chuah and Atanas Radinoff and Andrija Bogdanovic and Rastislav Moskal and Qi Jiang and Avijeet S Chopra and Elektra Papadopoulos and Jalaja Potluri and Francesco Passamonti},
  year = {2023},
  journal = {Blood},
  doi = {10.1182/blood-2023-173509},
  url = {https://doi.org/10.1182/blood-2023-173509}
}

RIS

TY  - JOUR
TI  - Transform-1: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, International Phase 3 Study of Navitoclax in Combination with Ruxolitinib Versus Ruxolitinib Plus Placebo in Patients with Untreated Myelofibrosis
AU  - Naveen Pemmaraju
AU  - Adam J Mead
AU  - Tim CP Somervaille
AU  - James K McCloskey
AU  - Francesca Palandri
AU  - Steffen Koschmieder
AU  - David Lavie
AU  - Brian Leber
AU  - Su-Peng Yeh
AU  - Maria Teresa Gómez-Casares
AU  - Emanuele Ammatuna
AU  - Ho-Jin Shin
AU  - Keita Kirito
AU  - Eric Jourdan
AU  - Timothy Devos
AU  - Hun S Chuah
AU  - Atanas Radinoff
AU  - Andrija Bogdanovic
AU  - Rastislav Moskal
AU  - Qi Jiang
AU  - Avijeet S Chopra
AU  - Elektra Papadopoulos
AU  - Jalaja Potluri
AU  - Francesco Passamonti
PY  - 2023
JO  - Blood
DO  - 10.1182/blood-2023-173509
UR  - https://doi.org/10.1182/blood-2023-173509
ER  -

APA

Pemmaraju, N., Mead, A. J., Somervaille, T. C., McCloskey, J. K., Palandri, F., Koschmieder, S., Lavie, D., Leber, B., Yeh, S., Gómez-Casares, M. T., Ammatuna, E., Shin, H., Kirito, K., Jourdan, E., Devos, T., Chuah, H. S., Radinoff, A., Bogdanovic, A., Moskal, R., Jiang, Q., Chopra, A. S., Papadopoulos, E., Potluri, J., & Passamonti, F. (2023). Transform-1: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, International Phase 3 Study of Navitoclax in Combination with Ruxolitinib Versus Ruxolitinib Plus Placebo in Patients with Untreated Myelofibrosis. Blood. https://doi.org/10.1182/blood-2023-173509

Source records

crossref · retrieved 2026-09-27T10:03:43.507Z